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Recent advances have identified a new paradigm for cerebral
malaria pathogenesis in which endothelial protein C receptor (EPCR)
is a major host receptor for sequestration of Plasmodium falcipa-
rum-infected erythrocytes (IEs) in the brain and other vital organs.
The parasite adhesins that bind EPCR are members of the IE variant
surface antigen family Plasmodium falciparum erythrocyte mem-
brane protein 1 (PfEMP1) containing specific adhesion domains
called domain cassette (DC) 8 and DC13. The binding interaction site
between PfEMP1 and EPCR has been mapped by biophysical and
crystallography studies using recombinant proteins. However, stud-
ies examining the interaction of native PfEMP1 on the IE surface
with EPCR are few. We aimed to study binding to EPCR by IEs
expressing DC8 and DC13 PfEMP1 variants whose recombinant pro-
teins have been used in key prior functional and structural studies.
IE binding to EPCR immobilized on plastic and on human brain en-
dothelial cells was examined in static and flow adhesion assays.
Unexpectedly, we found that IEs expressing the DC13 PfEMP1 variant
HB3var03 or IT4var07 did not bind to EPCR on plastic and the binding of
these variants to brain endothelial cells was not dependent on EPCR. IEs
expressing the DC8 variant IT4var19 did bind to EPCR, but this interac-
tion was inhibited if normal human serum or plasma was present,
raising the possibility that IE–EPCR interaction may be prevented
by plasma components under physiological conditions. These
data highlight a discrepancy in EPCR-binding activity between
PfEMP1 recombinant proteins and IEs, and indicate the critical
need for further research to understand the pathophysiological
significance of the PfEMP1–EPCR interaction.
cell adhesion | malaria | EPCR | PfEMP1 | endothelium
The major pathophysiological process implicated in cerebralmalaria is the sequestration of mature Plasmodium falcipa-
rum-infected erythrocytes (IEs) in the microvasculature of the
brain (1–4). Binding to endothelial cell receptors is mediated by
members of the variant IE surface protein family, P. falciparum
erythrocyte membrane protein 1 (PfEMP1) (5), encoded by var
genes (6). PfEMP1 variants are functionally classified into do-
main cassette (DC) types based on the conserved arrangement of
tandem cysteine-rich adhesion domains called Duffy binding-like
(DBL) and cysteine-rich interdomain region (CIDR) (7).
Over the past decade, significant progress has been made in
linking particular var gene groups to IE adhesion phenotype and
clinical disease. It has become apparent that IEs from patients
with cerebral and severe malaria predominantly express group A
or B/A var genes (8–10). Other studies show that DC8 (group B/A)
and DC13 (group A) variants are specifically associated with ce-
rebral and severe malaria (11–13). DC8 and DC13 variants have
also been shown to mediate IE binding to human brain endothelial
cells (HBECs) (14, 15), potentially explaining the association of
parasite DC8/DC13 expression with the clinical development of
cerebral malaria, due to sequestration in the brain. Later work
showed that DC8- and DC13-expressing IEs bind to endothelial
cells from diverse tissues and organs (16).
Binding of IEs to a particular receptor may be the cause of organ-
specific pathology, as in the case of pregnancy malaria, where se-
questration in the placenta is due to IEs binding to chondroitin
sulfate A (CSA) (17). For cerebral and severe malaria, recent work
suggests that endothelial protein C receptor (EPCR) may be the
key receptor, as DC8 and DC13 recombinant PfEMP1 molecules
bind with nanomolar affinity to EPCR (18), and a high-resolution
crystal structure of the interaction between EPCR and PfEMP1 has
been obtained identifying the DC13-EPCR–binding site (19).
Existing studies on the interaction of P. falciparum with EPCR
are largely based on PfEMP1 recombinant proteins, and detailed
studies of IEs expressing the DC8 and DC13 PfEMP1 variants
are few (20–22). We therefore investigated the role of EPCR in
IE adhesion using three P. falciparum parasite lines selected for
HBEC binding that predominantly express either a DC8 or
DC13 PfEMP1 (14). We show that there is a mismatch between
published recombinant protein data and the binding properties
of IEs, as IEs from two DC13-expressing parasite lines do not
bind to EPCR. IEs from the DC8-expressing parasite line do
bind EPCR, but the binding is inhibited by human plasma or
serum, raising questions as to the physiological relevance of
EPCR as a sequestration receptor in severe malaria.
Results
DC13-Expressing IEs Do Not Bind to EPCR Recombinant Protein in
Static and Flow Assays. Three parasite lines, derived by panning
on immortalized HBECs (HBEC-5i), that express the PfEMP1
variants HB3var03 (DC13), IT4var07 (DC13), and IT4var19
(DC8) (14) were used to study IE binding to EPCR. They were
chosen because recombinant CIDRα1 domain proteins of these
variants bind to EPCR with high affinity, with a Kd reported by
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Lau et al. (19) as 0.37 nM for HB3var03 (DC13), 1.3 nM for
IT4var07 (DC13), and 16 nM for IT4var19 (DC8). Also,
HB3var03 and IT4var07 recombinant domain proteins were used
to generate the crystal structure of PfEMP1 bound to EPCR
(19). The parasite lines were enriched for the variants of interest
by panning on HBEC-5i and cell sorting with variant-specific
antibodies, such that the “HB3var03” parasite line contained
50–80% of IEs expressing the HB3var03 PfEMP1 on their sur-
face, the “IT4var07” parasite line contained 30–50% of IEs
expressing IT4var07 and 1–5% of IEs expressing IT4var19, and
the “IT4var19” parasite line contained 50–80% of IEs expressing
IT4var19 and <1% of IEs expressing IT4var07 (Fig. S1). The
parasite lines are not monovariant, despite frequent selection,
because spontaneous var gene switching occurs in vitro, away
from the starting variant (23).
We tested the ability of the three parasite lines to bind to
recombinant (r) EPCR in static adhesion assays. DC8 IT4var19
IEs bound well to rEPCR as expected (Fig. 1A). Surprisingly,
DC13 HB3var03 and IT4var07 IEs did not bind to rEPCR (Fig. 1
B and C). All parasite lines showed binding to rCD36 significantly
above background levels (Fig. 1 A–C), most likely due to sub-
populations of parasites in these cultures expressing non-DC8/
DC13 PfEMP1 variants of group B and C type, known to bind
CD36 (14). To determine if the IEs that bound to rEPCR and
rCD36 expressed the DC8 or DC13 variants, we carried out im-
munofluorescence staining on the bound cells using variant-
specific antibodies. IEs bound to rEPCR from the IT4var19 culture
were confirmed as expressing the IT4var19/DC8 variant (Fig. 1A and
EPCR in Fig. S2), whereas the rCD36-binding IEs from the
same culture did not express IT4var19 (Fig. 2A and CD36 in
Fig. S2). In the IT4var07 culture, the small numbers of IEs that
bound to rEPCR all expressed IT4var19 and not IT4var07,
while the rCD36-binding IEs were negative with both anti-
bodies. Similarly, in the HB3var03 culture, the rCD36-binding
IEs were negative with antibodies to HB3var03 (Fig. S3A).
These data show that DC8 IT4var19 IEs bound to rEPCR in static
binding assays but that DC13 IT4var07 and HB3var03 IEs did not
bind to rEPCR, despite the nanomolar affinity for rEPCR shown
using IT4var07 and HB3var03 recombinant CIDRα1 domain
proteins (18, 19).
These experiments also revealed that IEs from the DC8
IT4var19 culture showed significant binding to PECAM-1 (Fig.
1A), while IEs from the DC13 IT4var07 culture showed significant
binding to NCAM-1 and hyaluronic acid (Fig. 1C). All three
parasite lines showed low-level binding to HABP-1 (Fig. 1 A–C),
but this was not statistically significant. Staining of the bound cells
with variant-specific antibodies showed that IT4var19 IEs bound
to PECAM-1 and HABP-1 and that HB3var03 IEs bound to
HABP-1 (Figs. S2 and S3). Attempts to stain IEs from the
IT4var07 culture bound to NCAM-1, HABP-1, and hyaluronic
acid were unsuccessful due to persistent loss of IEs from the plate.
We considered the possibility that rEPCR binding might be
absent in static assays and only revealed under flow conditions,
as seen with some selectin molecule interactions (24). However,
when tested at a shear stress of 1 dyne/cm2, representative of
physiological conditions in the microvasculature where seques-
tration occurs (25), DC8 IT4var19 IEs bound well to an rEPCR-
coated microslide but DC13 IT4var07 and HB3var03 IEs showed
levels of binding similar to the background levels seen with an
uncoated slide (dotted line in Fig. 1D).
In both static and flow assays, we used rEPCR from Sino Bi-
ologicals, as used in previous publications (18), and we also
tested the rEPCR preparation used for biophysical experiments
A B
C D
Fig. 1. DC8 IT4var19, but not DC13 HB3var03 and IT4var07, IEs bind to rEPCR.
IT4var19 IE (A), HB3var03 IE (B), and IT4var07 IE (C) binding to 50 μg/mL
receptors absorbed onto plastic dishes tested under static conditions is shown.
The filled circles are IEs that stained positive with DC8 or DC13 PfEMP1 ho-
mologous antibodies, and the empty circles did not stain with the DC8 or DC13
PfEMP1 antibodies. Half-filled circles are IEs that were not successfully stained
with antibodies due to loss of bound IEs during staining. The difference in
mean binding values compared with the PBS control from n ≥ 3 independent
experiments was analyzed by one-way ANOVA with Dunnett’s multiple com-
parisons test. **P < 0.01; ***P < 0.001; ****P < 0.0001. (D) Binding of IT4var19,
HB3var03, and IT4var07 IEs to 50 μg/mL rEPCR coated onto a microslide under
flow conditions at a shear stress of 1 dyne/cm2. The dotted line shows the
background levels of binding seen with an uncoated microslide. Each
data point is from an independent experiment, and the mean and SEM
are shown.
A B
C D
Fig. 2. DC8 IT4var19, but not DC13 HB3var03 and IT4var07, IE binding to
HBECs is reduced by EPCR antibodies and soluble recombinant protein
(rEPCR). IT4var19 IE (A), HB3var03 IE (B), and IT4var07 IE (C) binding to the
immortalized HBEC-5i line under static conditions with 20 μg/mL antibody or
soluble recombinant protein is shown. (D) Binding of the three parasite lines
to primary HBMECs under static conditions with 20 μg/mL soluble rEPCR.
Each data point is from an independent experiment, and the mean and SEM
are shown. The difference in mean values compared with control (with no
added antibody or protein) was analyzed by one-way ANOVA with Tukey’s
multiple comparisons test (A–C) and paired t test (D). **P < 0.01. The vertical
dotted line indicates experiments performed separately. mAb, monoclonal
antibody; pAb, polyclonal antibody.
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and crystallization studies (19) (a gift from Matt Higgins, Uni-
versity of Oxford, Oxford, UK). The same results, with binding of
DC8 IT4var19 IEs but not DC13 IT4var07 and HB3var03 IEs,
were seen with rEPCR from both sources.
DC13-Expressing IEs Do Not Bind to EPCR on HBECs. We next con-
sidered whether IEs could bind to EPCR constitutively expressed
on the cell surface, using the immortalized HBEC line HBEC-5i
(26). Binding of DC8 IT4var19 IEs to HBEC-5i was inhibited by
both monoclonal and polyclonal antibodies to EPCR, and by
soluble rEPCR (Fig. 2A). However, the EPCR antibodies and
soluble protein had no statistically significant effect on the binding
of DC13 HB3var03 and IT4var07 IEs to HBEC-5i (Fig. 2 B and
C). Similar results were seen with primary human brain micro-
vascular endothelial cells (HBMECs), with DC8 IT4var19 IE
binding being partially reduced by rEPCR, whereas there was no
effect on binding of DC13 HB3var03 or IT4var07 IEs (Fig. 2D).
Soluble rCD36 had no statistically significant effect on HBEC-5i
binding by any of the three parasite lines (Fig. 2 A–C), as expected,
because CD36 expression is absent or low on HBECs (26, 27).
To further examine the role of EPCR in IE binding to HBEC-5i,
EPCR expression was knocked down using siRNA. The expression
of EPCR on the surface of HBEC-5i was reduced by >50% at 48 h
after transfection, compared with HBEC-5i transfected with neg-
ative control siRNA (a scrambled sequence) (Fig. 3A). Consistent
with the antibody inhibition experiments discussed above, DC8
IT4var19 IEs showed significantly reduced binding to the HBEC-
5i–EPCR knockdown cells (Fig. 3B), whereas binding of DC13
HB3var03 and IT4var7 IEs was not significantly reduced (Fig. 3 C
and D). These data show that EPCR played a major role in the
binding of DC8 IT4var19 IEs to brain endothelial cells but that
binding of DC13 HB3var03 and IT4var07 IEs to brain endothelium
was unaffected by knocking down or inhibiting EPCR, suggesting
usage of other endothelial receptors.
Binding of DC13-Expressing IEs to HBECs Is Not Blocked by EPCR-
Binding Recombinant CIDR Proteins. Recombinant PfEMP1 domains
CIDRα1.1 of DC8 IT4var19 and CIDRα1.4 of DC13 HB3var03 and
IT4var07 have been shown previously to bind to EPCR with high
affinity (18, 19), and their binding site, which overlaps with the binding
site of protein C to EPCR, has been identified (19). We tested the
ability of CIDR recombinant proteins to block binding of IEs to
HBEC-5i. The CIDRα1.4 domains of DC13 HB3var03 and
IT4var07 were produced as soluble proteins of the expected molec-
ular mass in Escherichia coli (Fig. S4), but CIDRα1.1 of DC8
IT4var19 had degraded fragments and aggregates, so it was not used
further (not shown). Consistent with the above experiments, the two
EPCR-binding CIDRα1.4 proteins from DC13 HB3var03 and
IT4var07 inhibited binding of DC8 IT4var19 IEs to HBEC-5i (Fig.
4A) but had no significant effect on binding of DC13 HB3var03 and
IT4var07 IEs (Fig. 4 B and C). These data are consistent with the
known EPCR-binding activity of the CIDRα1.4 proteins (18, 19), and
suggest that other PfEMP1 domains apart from CIDRα1.4, or other
parasite adhesins, mediate binding of HB3var03 and IT4var07 IEs
to HBEC-5i.
The PfEMP1 Sequences of the DC8 and Two DC13-Expressing IEs
Match the Database. The N-terminal segment (NTS)-DBLα-
CIDRα1 domains of DC8 IT4var19, DC13 HB3var03, and IT4var07
IEs used for the experiments were sequenced from cDNA. The se-
quences for the HB3var03 and IT4var19 IEs were identical to NTS-
DBLα-CIDRα1 sequences on the VarDom 1.0 Server (www.cbs.dtu.
dk/services/VarDom/) (7) (Figs. S5 and S6). IT4var07 IEs had two
nucleotide changes that resulted in the following amino acid
changes: I268M in the DBLα domain and T678I in the
CIDRα1 domain (Fig. S7). These changes are outside the
binding site and do not involve the residues essential for
EPCR binding (19). Many other CIDRα1 domains that bind to
EPCR have isoleucine rather than threonine at the equivalent
amino acid position (19). It is therefore unlikely that these
changes account for the lack of EPCR binding by the IEs.
Human Serum and Plasma Inhibit Binding of DC8 IT4var19 IEs to HBEC-
5i and EPCR. Previous studies on EPCR binding by P. falciparum
IEs in vitro have used binding medium containing FBS or BSA to
block nonspecific binding (18, 19, 21, 22). To further examine the
physiological relevance of EPCR binding by DC8 IT4var19 IEs,
we examined binding to HBEC-5i in the presence of human
serum. We found that binding was greatly reduced when 5% or
10% pooled normal human serum was included in the binding
medium, an effect not seen with FBS (Fig. 5A). Some reduction
in the binding of DC13 HB3var03 IEs to HBEC-5i occurred in
the presence of both human and bovine serum, but this was less
marked than with DC8 IT4var19 IEs (Fig. 5B). Serum had no
significant effect on binding of DC13 IT4var07 IEs to HBEC-5i
(Fig. 5C). Heat-inactivated serum from a different pool of six
Scottish donors showed the same inhibitory effect on DC8
IT4var19 IE binding to HBEC-5i (Fig. S8A). Freshly prepared
serum and plasma from two different Scottish donors also
abolished binding of IT4var19 IEs to HBEC-5i (Fig. S8B), as did
serum from five individual donors different from those used in
the serum pools above (Fig. S8C).
The level of soluble EPCR (sEPCR) in serum/plasma from
healthy individuals ranges from ∼50–500 ng/mL (28, 29).
Therefore, we investigated whether sEPCR in serum might be
inhibiting the binding of IT4var19 IEs to HBEC-5i. A serum pool
from six Scottish donors was depleted of sEPCR with antibody-
coated beads, and the depletion was confirmed by ELISA using
an rEPCR standard curve. The starting serum pool contained
57 ng/mL sEPCR, whereas EPCR was below the limit of de-
tection (<0.3 ng/mL) after depletion. The EPCR-depleted serum
A B
C D
Fig. 3. DC8 IT4var19, but not DC13 HB3var03 and IT4var07, IE binding to
the HBEC line HBEC-5i is reduced by EPCR siRNA knockdown. (A) Expression
of EPCR on HBEC-5i by immunostaining and flow cytometry. HBEC-5i was
transfected with EPCR siRNA (orange) or a negative control siRNA (blue).
Forty-eight hours after transfection, HBEC-5i was stained with 1 μg/mL goat
polyclonal antibody to EPCR (orange/blue) or goat IgG-negative control
(red), followed by Alexa Fluor 488 donkey anti-goat IgG at a 1:1,500 dilution.
Data shown are representative of four similar experiments. (B–D) Binding of
IEs to HBEC-5i transfected with control siRNA or EPCR siRNA under static
conditions. The data shown are the mean and SEM from four independent
experiments. The difference in mean values compared with the siRNA con-
trol was analyzed by a two-tailed paired t test. *P < 0.05. NS, not significant.
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inhibited DC8 IT4var19 IE binding to HBEC-5i to the same
extent as the normal serum pool (Fig. 5D).
EPCR is known to bind lipid (phosphatidylcholine) from serum
in its hydrophobic groove (30), so we also tested whether delipi-
dated serum affected binding. Delipidated serum showed the same
inhibitory activity as normal human serum (Fig. S8D). Human cord
blood serum and plasma also showed the same inhibitory effect on
DC8 IT4var19 IE binding to HBEC-5i as adult sera (Fig. S8D).
To test directly whether serum blocks binding of ITvar19 IEs
to EPCR, in vitro static binding assays to recombinant receptors
were carried out. Addition of 10% pooled human serum to the
binding medium caused a significant reduction in binding to
rEPCR (Fig. 6). The presence of human serum did not signifi-
cantly alter binding to CD36, ICAM-1, or CSA, but did signifi-
cantly increase binding to HABP-1 (Fig. 6).
High-Molecular-Weight Serum Components, Including IgG, Block
Binding of DC8 IT4var19 IEs to HBEC-5i. To further investigate the
nature of the adhesion-blocking component in serum, we frac-
tionated serum into >100-kDa and <100-kDa fractions. The
adhesion-blocking activity was present in the >100-kDa fraction
(Fig. S8E). We found that purified human IgG, but not purified
IgM, could partially block binding of IT4var19 IEs to HBEC-5i
(Fig. S8F). However, IgG-depleted serum retained full inhibitory
activity (Fig. S8F), suggesting that serum components other than
IgG also have adhesion-blocking effects.
Discussion
PfEMP1 variants are large complex multidomain proteins that,
through their binding to receptors expressed on host endothelial
cell surfaces, play a critical role in determining the outcome of
P. falciparum infections. However, to date, most of our un-
derstanding of the binding specificity and affinity of PfEMP1
molecules for their host receptors comes from studies of indi-
vidual recombinant PfEMP1 domains. Individual domains may
show different properties when expressed in the context of the
complete PfEMP1 protein (31). Therefore, to more fully un-
derstand PfEMP1–receptor interactions, it is essential to study
the binding of full-length native PfEMP1 variants. Here, we fo-
cused on two PfEMP1 variant types containing CIDRα1 domains
that are essential components of DC8 and DC13, which bind
similarly to the endothelial protein EPCR in recombinant pro-
tein studies (18, 19). The results presented here show that the
binding properties of PfEMP1 expressed on the IE surface can
be remarkably different from those indicated by recombinant
protein experiments. DC8-expressing IEs did bind to EPCR-
expressing endothelial cells, and the binding was blocked by
EPCR-specific antibodies or by siRNA knockdown of EPCR. In
contrast, DC13-expressing IEs did not bind to EPCR protein in
static assays, and their binding to endothelial cells was not de-
pendent on the expression of EPCR, as it was not affected by the
addition of EPCR-specific antibodies or by knockdown of
EPCR. How might these observations be explained? The native
full-length DC13 PfEMP1 may have significantly reduced affinity
for EPCR. This possibility is consistent with the observations of
Avril et al. (22), who demonstrated binding of DC13-expressing
IEs to CHO cells expressing high levels of EPCR, which may
increase the avidity of binding, compensating for the lower af-
finity of DC13 PfEMP1 for EPCR.
A second explanation for the discrepancy in results is that
native PfEMP1 molecules on the surface of IEs adopt a different
conformation from that of PfEMP1 recombinant domains, such
that the EPCR-binding site is masked on IEs. If this is true, it is
possible that allosteric changes (e.g., upon engaging with another
receptor) might alter PfEMP1 conformation to expose or in-
terfere with the EPCR-binding domain. In such a scenario, IE
binding to EPCR on endothelial cells might depend on the
particular combination of host receptors available. Other recent
studies describe the importance of dual-binding phenotypes,
A B
C
Fig. 4. DC8 IT4var19, but not DC13 HB3var03 and IT4var07, IE binding to
the HBEC cell line HBEC-5i is reduced by recombinant PfEMP1 CIDR proteins.
IT4var19 IE (A), HB3var03 IE (B), and IT4var07 IE (C) binding to HBEC-5i under
static conditions with 50 μg/mL soluble recombinant PfEMP1 protein is
shown. The data shown are the mean and SEM from three independent
experiments. The difference in mean binding values compared with control
(with no added protein) was analyzed by one-way ANOVA with Dunnett’s
multiple comparisons test. *P < 0.05. NS, not significant.
A B
C D
Fig. 5. DC8 IT4var19, but not DC13 HB3var03 and IT4var07, IE binding to
the HBEC line HBEC-5i is abolished by human serum. IT4var19 IE (A),
HB3var03 IE (B), and IT4var07 IE (C) binding to HBEC-5i under static condi-
tions with pooled human or FBS is shown. (D) Binding of IT4var19 IEs to
HBEC-5i with sEPCR-depleted pooled human serum. Each data point is from
an independent experiment, and the mean and SEM are shown. The dif-
ference in mean values compared with the “No Serum” control (A–C) or
“0.1% BSA” control (D) was analyzed by one-way ANOVA with Dunnett’s
multiple comparisons test. **P < 0.01; ***P < 0.001; ****P < 0.0001.
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suggesting that DC13 variants interact with both EPCR and
ICAM-1 to bind to endothelial cells (22, 32). Other authors show
that some DC8 PfEMP1 variants bind to HABP-1 (also known as
gC1qR) and suggest that this receptor is important for IE se-
questration in severe malaria (33).
Another possible explanation for the mismatch between pub-
lished recombinant protein data and the adhesion properties of
IEs is that a human serum/plasma component might bind to
PfEMP1 or EPCR in our assays and block the binding interaction
site. We found that IEs expressing a DC8 variant (IT4var19) did
bind to rEPCR and to brain endothelial cells via EPCR in serum-
free medium (Figs. 1–4). However, addition of 5–10% normal
human serum or plasma to the binding medium inhibited these
adhesion interactions (Figs. 5 and 6 and Fig. S8). A difference
between our data and other published work on EPCR using DC8-
expressing IEs is that previous binding studies have used FBS (18,
19) or BSA (21, 22) in the binding medium, neither of which
blocks IE adhesion to EPCR (Fig. 5). Our data suggest that the
serum factor that blocks binding of DC8-expressing IEs is unlikely
to be sEPCR, as sEPCR-depleted serum showed the same in-
hibitory effect (Fig. 5D). EPCR has anMHC class 1 structural fold
and, under physiological conditions, contains lipid in its hydro-
phobic groove (30). However, delipidated serum showed the same
inhibitory effect as normal human serum (Fig. S8). Fractionation
experiments showed that the serum component(s) responsible for
inhibiting EPCR binding are >100 kDa and may include non-
immmune IgG (Fig. S8). However, IgG-depleted serum fully
inhibited binding, suggesting that other high-molecular-weight
components might affect the ability of DC8-expressing IEs to bind
to EPCR under physiological exposure to plasma in vivo.
Previous work has shown that distinct DC8 and DC13 PfEMP1
subsets identified on the basis of sequence similarity have evolved
(7), which share biological functions such as the interaction with
EPCR demonstrated in recombinant protein studies (18, 19), and
that parasite expression of these subsets is associated with severe
and cerebral malaria (11, 13, 34, 35). Our findings do not un-
dermine these important observations, and they do not contradict
work suggesting that the loss of EPCR on brain endothelial cells
may contribute to coagulopathy and impaired endothelial barrier
integrity in cerebral malaria (36). Our results do, however, raise ques-
tions regarding the identification of EPCR as the major host receptor
for IE sequestration in the brain during cerebral malaria. Our data,
together with published studies showing that DC8- and DC13-express-
ing IEs bind to other receptors such as HABP-1 (33) and ICAM-1 (22,
32), support a reinterpretation of the cerebral malaria paradigm to one
that downplays the role of a single receptor in the brain and, instead,
emphasizes that IEs interact with multiple host receptors to bring about
sequestration, as suggested by other authors (20, 37, 38). It remains
possible that even if sequestration in severe malaria is mediated by other
receptors, PfEMP1 might engage with EPCR on endothelial cells to
modify EPCR’s endothelial-protective functions (39). However, further
work is needed to determine if such functional interactions do occur,
especially in the presence of human plasma.
Materials and Methods
Ethics Statement. Human erythrocytes and sera were obtained following receipt
of informed consent fromblooddonors, with approval from the ScottishNational
Blood Transfusion Service Committee for the Governance of Blood and Tissue
Samples for Nontherapeutic Use (reference SNBTS 12-35). In addition, anonymous
blood donations were obtained from the Interstate Blood Bank, Memphis, TN.
P. falciparum Culture and Parasite Lines. Parasites were cultured as described
elsewhere (14). The parasite lines HB3-HBEC and IT-HBEC were generated pre-
viously by panning on HBEC-5i (40). Their var gene transcriptional profiles were
determined by variant surface antigen (VSA)-supplementedmicroarray and reverse
transcriptase PCR and sequencing (14). Specific antibodies to HB3var03 were used
to detect the PfEMP1 variant on the surface of IEs by immunofluorescence assay
(IFA) and flow cytometry as described elsewhere (14, 22). The IT-HBEC parasite line
had two predominant variants: one DC13 encoded by IT4var07 and one DC8
encoded by IT4var19 (14). Antibodies raised to IT4var07 and IT4var19 were used in
fluorescence-activated cell sorting to generate two separate parasite lines,
IT4var19 and IT4var07. The IT4var07 line underwent rapid var gene switching, so
that even with frequent panning, it was not possible to maintain more than 30–
50% of IEs expressing IT4var07. The three parasite lines studied here do not form
rosettes or platelet-mediated clumps (14), and do not bind nonimmune IgM or IgG
on IEs.
Static Adhesion Assays to Receptor Molecules Immobilized on Plastic. The re-
ceptor-binding assays were done as previously described (14) with 50 μg/mL
rEPCR, PECAM-1, ICAM-1, CD36, NCAM-1, HABP-1, or VCAM-1 or with purified
heparin sodium salt, CSA, or hyaluronic acid spotted onto plastic dishes. IEs
were suspended at 2% hematocrit (Ht) in bicarbonate-free DMEM-F12 Ham
(D8900; Sigma)/0.1% BSA (pH 7.2–7.4), hereafter called “binding medium.”
The detailed method is provided in SI Materials and Methods.
IFA with PfEMP1 Antibodies on the Bound IEs. Binding assayswere carried out as
above, and after washing off unbound cells, 25 μg/mL purified polyclonal IgG
from a rabbit immunized with NTS-DBLα1 of HB3var03 (14), IT4var07 (22),
IT4var19 (22), or IgG from a nonimmunized rabbit and diluted in PBS/1% BSA
was added to the spot and incubated for 30 min. The dishes were washed
twice with PBS for 5 min. Then, 50 μL of a 1:500 dilution of Alexa Fluor
488 goat anti-rabbit IgG (A-11034; Invitrogen) in PBS/0.1% BSA/1 μg/mL DAPI
was added to the spot and incubated for 30 min in the dark. Dishes were
washed twice as above and air-dried; DABCO glycerol mountant (290734;
Sigma) or Fluoromount (F4680; Sigma) was then added to the spot, and the
samples then sealed with a coverslip for viewing by fluorescence microscopy
with a 100× objective. Pictures were taken with a YenCam digital camera.
Flow Adhesion Assay with rEPCR. A μ-Slide I 0.8 Luer (80191; ibidi GmBH) was
coated with 50 μg/mL rEPCR for 2 h in a humid box at 4 °C. The EPCR was
then removed, replaced with PBS/1% BSA, and incubated overnight at 4 °C.
An ibidi pump system (10902; ibidi GmBH) was set up, and IEs at 1% Ht and
50–90% parasitemia in binding medium were flowed unidirectionally
through the EPCR-coated microslide at a shear stress of 1 dyne/cm2. After
5 min, the number of IEs bound under continuous flow was counted per
10 fields viewed with a 40× objective.
HBEC Lines and Culture. HBEC-5i, an immortalized HBEC line (26, 40), was cultured
as previously described (14). The brain endothelial characteristics of HBEC-5i were
confirmed by staining positive in the IFA for cytoplasmic von Willebrand factor
(vWF) andmembrane Glut-1, and negative for the fibroblast marker smoothmuscle
actin (SMA) and for CD36. As previously reported, HBEC-5i is negative for PECAM-1/
CD31, a protein usually found on endothelial cells (26). Primary HBECs (HBMECs)
from ScienCell (SC-1000), which stain positively for cytoplasmic vWF and membrane
PECAM-1, were cultured as described (14) and were used up to passage 7.
HBEC-Binding Assays and Inhibition with Antibodies and Recombinant Proteins.
For binding assays, HBEC-5i or HBMECs were seeded onto gelatin-coated 48-well
Fig. 6. Human serum inhibits adhesion of DC8 IT4var19-expressing IEs to
rEPCR. IT4var19 IE binding to 50 μg/mL receptors absorbed onto plastic
dishes tested under static conditions in binding medium with 10% pooled
human serum or 0.1% BSA (No serum) is shown. The mean and SEM from
three independent experiments are shown. The differences in mean values
compared with the No serum controls were analyzed by a two-tailed paired
t test for each receptor. *P < 0.05; **P < 0.01. NS, not significant.
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plates to reach 80–90% confluency on the day of the assay. Gelatin-purified
pigmented trophozoites at 50–90% parasitemia were suspended in binding
medium (as described above) at 2%Ht. To test the inhibitory effect of antibodies,
HBEC-5i was preincubated with 20 μg/mL goat polyclonal antibody to human
EPCR (AF2245; R&D Systems), rat monoclonal antibody to human EPCR (clone
RCR-252, HM2145; Hycult), or isotype control rat IgG1 (HI3001; Hycult) or poly-
clonal goat IgG (AB-108-C; R&D Systems) for 20 min before addition of IEs. To test
the inhibitory effect of recombinant proteins, IEs were resuspended at 2% Ht
with 20 μg/mL soluble rEPCR or rCD36 in binding medium, or the HBEC-5i was
preincubated with 50 μg/mL recombinant CIDRα1.4 proteins of DC13
HB3var03 or IT4var07 in binding medium/0.1% BSA for 20 min. After addition of
IEs to the HBEC-5i, the plate was incubated for 75 min at 37 °C with resuspension
of cells by tilting the plate after 30 and 60 min. The cells were washed by re-
moving the supernatant and adding warm binding medium using a plastic Pas-
teur pipette and gently rocking the plate. The washing was repeated until there
were very few or no unbound IEs remaining. The cells were fixed with 2% glu-
taraldehyde in PBS for 1 h and stained with 5% Giemsa for 10 min.
Binding of IEs to EPCR siRNA-Transfected HBEC-5i. HBEC-5i at 60–80% con-
fluency was transfected with an equal volume of 10 μM EPCR siRNA (sc-
39932; Santa Cruz Biotechnology) and Lipofectamine RNAiMAX Transfection
Reagent (13778075; Life Technologies), each diluted with Opti-MEM re-
duced serum medium (31985062; Life Technologies) at a ratio of 3:50. HBEC-
5i transfected with control A siRNA (sc-37007; Santa Cruz Biotechnology)
was used as a negative control. Details of the transfection are provided in SI
Materials and Methods. For the binding assay, gelatin-purified pigmented
trophozoites at 2% Ht in 190 μL of binding medium/0.1% BSA were added
to each of two wells in a 48-well plate containing EPCR siRNA-transfected
HBEC-5i or control siRNA-transfected HBEC-5i and incubated for 60 min at 37 °C.
The cells were gently resuspended after 15 and 30 min and washed, fixed, and
stained as above.
HBEC-5i–Binding Inhibition with Serum and Plasma. Binding assays were car-
ried out as above with gelatin-purified pigmented trophozoites (50–90%
parasitemia with the exception of IT4var19 IEs in Fig. 5A, where 5% para-
sitemia was used) in binding medium at 2% Ht with added 5% or 10% (vol/
vol) pooled human serum from multiple donors (Scottish National Blood
Transfusion Service), EPCR-depleted human serum (described in SI Materials
and Methods), FBS (10500064; Thermo Fisher Scientific), or 0.1% BSA (A0336;
Sigma–Aldrich). Additional serum components and fractionation are de-
scribed in SI Materials and Methods.
Statistical Analyses and Graphing. Statistical analyses and graphs were pre-
pared using GraphPad Prism (v7.0b; GraphPad Software, Inc.). Technical
replicates based on counts of duplicate spots or wells were averaged to
generate a binding value for each receptor or condition in each experiment.
Statistical analysis was carried out on the binding values from n ≥ 2 in-
dependent experiments using two-tailed paired t tests or one-way ANOVA
with Dunnett’s or Tukey’s multiple comparisons test. Asterisks indicate *P <
0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001, and NS indicates no
statistical significance (P > 0.05).
ACKNOWLEDGMENTS. This work was funded by a studentship award from
the Darwin Trust of Edinburgh, the Wellcome Trust (Grants 084226 and
095831), and the NIH Intramural Research Program.
1. Marchiafava E, Bignami A (1894) On Summer-Autumnal Fever (The New Sydenham
Society, London).
2. Taylor TE, Molyneux ME (2015) The pathogenesis of pediatric cerebral malaria: Eye
exams, autopsies, and neuroimaging. Ann N Y Acad Sci 1342:44–52.
3. MacPherson GG, Warrell MJ, White NJ, Looareesuwan S, Warrell DA (1985) Human
cerebral malaria. A quantitative ultrastructural analysis of parasitized erythrocyte
sequestration. Am J Pathol 119:385–401.
4. Milner DA, Jr, et al. (2015) Quantitative assessment of multiorgan sequestration of
parasites in fatal pediatric cerebral malaria. J Infect Dis 212:1317–1321.
5. Baruch DI, et al. (1997) Identification of a region of PfEMP1 that mediates adherence
of Plasmodium falciparum infected erythrocytes to CD36: Conserved function with
variant sequence. Blood 90:3766–3775.
6. Su X-Z, et al. (1995) A large and diverse family gene family (var) encodes 200-350 kD
proteins implicated in the antigenic variation and cytoadherence of Plasmodium
falciparum-infected erythocytes. Cell 82:89–99.
7. Rask TS, Hansen DA, Theander TG, Gorm Pedersen A, Lavstsen T (2010) Plasmodium
falciparum erythrocyte membrane protein 1 diversity in seven genomes–Divide and
conquer. PLOS Comput Biol 6:e1000933.
8. Kirchgatter K, Portillo HdA (2002) Association of severe noncerebral Plasmodium
falciparum malaria in Brazil with expressed PfEMP1 DBL1 alpha sequences lacking
cysteine residues. Mol Med 8:16–23.
9. Kyriacou HM, et al. (2006) Differential var gene transcription in Plasmodium falciparum
isolates from patients with cerebral malaria compared to hyperparasitaemia. Mol
Biochem Parasitol 150:211–218.
10. Warimwe GM, et al. (2012) Prognostic indicators of life-threatening malaria are as-
sociated with distinct parasite variant antigen profiles. Sci Transl Med 4:129ra45.
11. Lavstsen T, et al. (2012) Plasmodium falciparum erythrocyte membrane protein
1 domain cassettes 8 and 13 are associated with severe malaria in children. Proc Natl
Acad Sci USA 109:E1791–E1800.
12. Bertin GI, et al. (2013) Expression of the domain cassette 8 Plasmodium falciparum eryth-
rocyte membrane protein 1 is associated with cerebral malaria in Benin. PLoS One 8:e68368.
13. Bernabeu M, et al. (2016) Severe adult malaria is associated with specific PfEMP1 adhesion
types and high parasite biomass. Proc Natl Acad Sci USA 113:E3270–E3279.
14. Claessens A, et al. (2012) A subset of group A-like var genes encodes the malaria
parasite ligands for binding to human brain endothelial cells. Proc Natl Acad Sci USA
109:E1772–E1781.
15. Avril M, et al. (2012) A restricted subset of var genes mediates adherence of Plas-
modium falciparum-infected erythrocytes to brain endothelial cells. Proc Natl Acad Sci
USA 109:E1782–E1790.
16. Avril M, Brazier AJ, Melcher M, Sampath S, Smith JD (2013) DC8 and DC13 var genes
associated with severe malaria bind avidly to diverse endothelial cells. PLoS Pathog 9:
e1003430.
17. Fried M, Duffy PE (1996) Adherence of Plasmodium falciparum to chondroitin sulfate
A in the human placenta. Science 272:1502–1504.
18. Turner L, et al. (2013) Severe malaria is associated with parasite binding to endo-
thelial protein C receptor. Nature 498:502–505.
19. Lau CK, et al. (2015) Structural conservation despite huge sequence diversity allows
EPCR binding by the PfEMP1 family implicated in severe childhood malaria. Cell Host
Microbe 17:118–129.
20. Gillrie MR, et al. (2015) Diverse functional outcomes of Plasmodium falciparum ligation
of EPCR: Potential implications for malarial pathogenesis. Cell Microbiol 17:1883–1899.
21. Sampath S, et al. (2015) Plasmodium falciparum adhesion domains linked to severe ma-
laria differ in blockade of endothelial protein C receptor. Cell Microbiol 17:1868–1882.
22. Avril M, Bernabeu M, Benjamin M, Brazier AJ, Smith JD (2016) Interaction between
endothelial protein C receptor and intercellular adhesion molecule 1 to mediate binding
of Plasmodium falciparum-infected erythrocytes to endothelial cells. MBio 7:e00615.
23. Peters JM, Fowler EV, Krause DR, Cheng Q, Gatton ML (2007) Differential changes in
Plasmodium falciparum var transcription during adaptation to culture. J Infect Dis
195:748–755.
24. Finger EB, et al. (1996) Adhesion through L-selectin requires a threshold hydrody-
namic shear. Nature 379:266–269.
25. Cooke BM, Morris-Jones S, Greenwood BM, Nash GB (1993) Adhesion of parasitized
red blood cells to cultured endothelial cells: A flow-based study of isolates from
Gambian children with falciparum malaria. Parasitology 107:359–368.
26. Wassmer SC, Combes V, Candal FJ, Juhan-Vague I, Grau GE (2006) Platelets potentiate brain
endothelial alterations induced by Plasmodium falciparum. Infect Immun 74:645–653.
27. Turner GDH, et al. (1994) An immunohistochemical study of the pathology of fatal
malaria. Evidence for widespread endothelial activation and a potential role for in-
tercellular adhesion molecule-1 in cerebral sequestration. Am J Pathol 145:
1057–1069.
28. Stearns-Kurosawa DJ, Burgin C, Parker D, Comp P, Kurosawa S (2003) Bimodal dis-
tribution of soluble endothelial protein C receptor levels in healthy populations.
J Thromb Haemost 1:855–856.
29. Uitte de Willige S, et al. (2004) Haplotypes of the EPCR gene, plasma sEPCR levels and
the risk of deep venous thrombosis. J Thromb Haemost 2:1305–1310.
30. Oganesyan V, et al. (2002) The crystal structure of the endothelial protein C receptor
and a bound phospholipid. J Biol Chem 277:24851–24854.
31. Dahlbäck M, Nielsen MA, Salanti A (2010) Can any lessons be learned from the am-
biguous glycan binding of PfEMP1 domains? Trends Parasitol 26:230–235.
32. Lennartz F, et al. (2017) Structure-guided identification of a family of dual receptor-
binding PfEMP1 that is associated with cerebral malaria. Cell Host Microbe 21:403–414.
33. Magallón-Tejada A, et al. (2016) Cytoadhesion to gC1qR through Plasmodium falciparum
erythrocyte membrane protein 1 in severe malaria. PLoS Pathog 12:e1006011.
34. Jespersen JS, et al. (2016) Plasmodium falciparum var genes expressed in children with
severe malaria encode CIDRα1 domains. EMBO Mol Med 8:839–850.
35. Mkumbaye SI, et al. (2017) The severity of Plasmodium falciparum infection is asso-
ciated with transcript levels of var genes encoding endothelial protein C receptor-
binding P. falciparum erythrocyte membrane protein 1. Infect Immun 85:e00841.
36. Moxon CA, et al. (2013) Loss of endothelial protein C receptors links coagulation and
inflammation to parasite sequestration in cerebral malaria in African children. Blood
122:842–851.
37. Ho M (2014) EPCR: Holy grail of malaria cytoadhesion? Blood 123:157–159.
38. Bernabeu M, Smith JD (2017) EPCR and malaria severity: The center of a perfect
storm. Trends Parasitol 33:295–308.
39. Mohan Rao LV, Esmon CT, Pendurthi UR (2014) Endothelial cell protein C receptor: A
multiliganded and multifunctional receptor. Blood 124:1553–1562.
40. Claessens A, Rowe JA (2012) Selection of Plasmodium falciparum parasites for cy-
toadhesion to human brain endothelial cells. J Vis Exp e3122.
6 of 6 | www.pnas.org/cgi/doi/10.1073/pnas.1712879115 Azasi et al.
